重庆西山科技股份有限公司 关于召开 2025 年第三季度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 证券代码：688576 证券简称：西山科技 公告编号：2025-045 （如遇特殊情况，参会人员可能进行调整） 一、 说明会类型 重庆西山科技股份有限公司（以下简称"公司"）于 2025 年 10 月 31 日在上 海证券交易所网站（www.sse.com.cn）披露《2025 年第三季度报告》。为便于广 大投资者更加全面深入地了解公司经营业绩、发展战略等情况，公司计划于 2025 年 11 月 21 日（星期五）15:00-16:00 在"价值在线"（www.ir-online.cn）举 办重庆西山科技股份有限公司 2025 年第三季度业绩说明会，与投资者进行沟通 和交流，广泛听取投资者的意见和建议。 会议召开时间：2025 年 11 月 21 日（星期五）15:00-16:00 会议召开地点：价值在线（www.ir-online.cn） 会议召开方式：网络互动方式 会 议 问 题 征 ...

Core Viewpoint - The company reported a strong recovery in Q3 2025, with significant growth in revenue and profit, indicating a potential turning point despite challenges in the first three quarters of the year [1][2]. Financial Performance - For the first three quarters of 2025, the company achieved revenue of 231 million yuan, an increase of 11.32%, while net profit attributable to shareholders was 43 million yuan, a decrease of 34.14% [1]. - In Q3 alone, the company recorded revenue of 76 million yuan, up 35.45%, and a net profit of 9 million yuan, up 28.75% [1]. - The decline in net profit for the first three quarters was primarily due to a drop in gross profit from a specific product, increased depreciation and operating expenses from a new facility, and reduced investment income [1]. Business Segments - The orthopedic business has become a core growth engine, with its revenue share increasing from 24% to 35% year-on-year [2]. - The spinal surgery consumables saw over 90% growth, while joint and trauma-related consumables grew by over 70% [2]. - The company experienced a 45% increase in sales volume of a specific biopsy product due to price reductions from procurement policies, enhancing market demand [2]. R&D and Internationalization - The company has made significant advancements in R&D, launching new surgical power devices and obtaining certifications for various products, enhancing its competitive edge [3]. - In 2025, the company added 112 new patents, bringing the total to 1,368, showcasing its ongoing innovation capabilities [3]. - The company achieved key milestones in internationalization, with several products receiving EU CE-MDR certification, facilitating entry into international markets [3]. Profit Forecast and Investment Suggestions - The projected net profits for 2025-2027 are 61 million, 77 million, and 95 million yuan, respectively [4]. - As a leading domestic player in surgical power devices, the company is well-positioned to benefit from the ongoing shift towards disposable consumables and the introduction of innovative products [4].

重庆西山科技股份有限公司 2025 年第三次临时股东大会会议资料 证券代码：688576 证券简称：西山科技 重庆西山科技股份有限公司 2025年第三次临时股东大会 会议资料 2025 年 11 月 1 | 《关于补选公司第四届董事会非独立董事的议案》 9 | | --- | 重庆西山科技股份有限公司 2025 年第三次临时股东大会会议资料 2025 年第三次临时股东大会会议须知 为了维护全体股东的合法权益，确保公司股东大会的正常秩序和议事效率， 根据《中华人民共和国公司法》（以下简称"《公司法》"）《中华人民共和国 证券法》（以下简称"《证券法》"）《上市公司股东会规则》以及《重庆西山 科技股份有限公司章程》（以下简称"《公司章程》"）等相关规定，重庆西山 科技股份有限公司（以下简称"公司"）特制订以下会议须知，请出席股东大会 的全体人员遵照执行。 一、会议期间，全体出席人员应以维护股东的合法权益、保证股东大会的正 常秩序和议事效率为原则，认真履行法定义务，自觉遵守股东大会纪律，不得侵 犯其他股东的权益，以确保股东大会的正常秩序。 二、为保证股东大会的严肃性和正常秩序，切实维护与会股东的合法权益， 请出席股 ...

Core Viewpoint - The company reported strong financial performance in Q3, with significant growth in revenue and net profit, driven by increased sales in orthopedic products and successful product certifications [1][2]. Financial Performance - In Q3, the company achieved operating revenue of 75.76 million yuan, a year-on-year increase of 35.45% [1] - The net profit attributable to shareholders reached 9.01 million yuan, up 28.75% year-on-year [1] - The net profit after deducting non-recurring items was 5.67 million yuan, reflecting a 24.27% increase compared to the previous year [1] Product Performance - Revenue from orthopedic-related power products increased from 24% to 35% of total revenue year-on-year, becoming a major income source for the company [1] - Sales of disposable breast biopsy needles grew by 45% compared to the same period last year, indicating the effectiveness of the company's price-volume strategy [1] - Significant growth was observed in the surgical power device segment, with spinal surgery consumables increasing by over 90% and trauma-related consumables by over 70% year-on-year [1] Regulatory Achievements - The company successfully obtained CE-MDR certification for its neurosurgery, orthopedic, ENT, and breast surgery power device products, which will positively impact future international product access and sales [1] - The penetration of plasma devices and consumables has increased, with breakthroughs in markets such as Shanxi, Anhui, Guangdong, Shaanxi, Gansu, Ningxia, and Chongqing [1] Innovation and R&D - The company added 112 new patents this year, bringing the total to 1,368 effective patents, including 768 for surgical power devices, 243 for endoscopes, and 263 for energy surgical equipment [2] - New surgical power devices for ENT and neurosurgery have been developed and launched, receiving market recognition [2] - Key technological breakthroughs in endoscopic products have been achieved, providing new growth momentum for the company [2]

Group 1 - The core viewpoint of the news is that Xishan Technology's stock performance and financial metrics indicate a mixed outlook, with a slight decline in stock price and significant financing activity [1][2]. - On October 30, Xishan Technology's stock fell by 0.72%, with a trading volume of 17.36 million yuan, and a net financing purchase of 849,300 yuan [1]. - As of October 30, the total margin balance for Xishan Technology was 93.81 million yuan, accounting for 6.60% of its market capitalization, indicating a high level of financing activity compared to the past year [1]. Group 2 - For the period from January to September 2025, Xishan Technology reported a revenue of 231 million yuan, representing a year-on-year growth of 11.32%, while the net profit attributable to shareholders decreased by 34.14% to 43.40 million yuan [2]. - The company has distributed a total of 94.07 million yuan in dividends since its A-share listing [3]. - As of September 30, 2025, Xishan Technology had 5,303 shareholders, with an average of 4,109 circulating shares per shareholder, indicating a slight increase in shareholder numbers but a decrease in average shares held [2].

Core Viewpoint - Xishan Technology reported a revenue of 231 million yuan for the first three quarters of 2025, marking an 11.32% year-on-year increase, while the net profit attributable to shareholders decreased by 34.14% to 43.395 million yuan [1][2]. Financial Performance - The basic earnings per share for the reporting period was 0.96 yuan, with a weighted average return on equity of 2.51% [2]. - The company's gross margin for the first three quarters was 64.27%, down 6.50 percentage points year-on-year, and the net margin was 18.80%, a decrease of 12.98 percentage points compared to the same period last year [2]. - In Q3 2025, the gross margin was 62.16%, down 8.77 percentage points year-on-year and 1.41 percentage points quarter-on-quarter, while the net margin was 11.90%, a decline of 0.62 percentage points year-on-year and 13.79 percentage points quarter-on-quarter [2]. Expense Analysis - Total operating expenses for Q3 2025 were 111 million yuan, an increase of 12.22 million yuan year-on-year, with an expense ratio of 48.13%, up 0.45 percentage points from the previous year [2]. - Breakdown of expenses showed a 2.54% decrease in sales expenses, a 66.65% increase in management expenses, a 6.72% increase in R&D expenses, and a 5.16% increase in financial expenses [2]. Shareholder Information - As of the end of Q3 2025, the total number of shareholders was 5,273, an increase of 427 (8.81%) from the end of the previous half-year, while the average market value per shareholder decreased by 4.93% from 597,200 yuan to 567,700 yuan [2]. Company Overview - Xishan Technology, established on December 23, 1999, and listed on June 6, 2023, is located in Chongqing and specializes in the research, production, and sales of surgical power devices [3]. - The main business revenue composition includes surgical power devices (92.10%), with consumables accounting for 76.74%, complete machines for 10.06%, and other components for 7.87% [3].

证券代码：688576 证券简称：西山科技 公告编号：2025-044 关于召开2025年第三次临时股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 重庆西山科技股份有限公司 2025年第三次临时股东大会 召开日期时间：2025 年 11 月 18 日 14 点 30 分 召开地点：重庆市两江新区康美街道康竹路 2 号西山科技 B 栋行政楼 6 楼 会议室 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 11 月 18 日 （四） 现场会议召开的日期、时间和地点 （一） 股东大会类型和届次 | 序号 | 议案名称 | 投票股东类型 | | --- | --- | --- | | | | 股股东 A | | 非累积投票议案 | | | | 1 | 关于取消监事会及修订《公司章程》的议案 | √ | | 2 | 关于修订及制定公司部分治理制度的议案 | √ | | 3 | 关于补选公司第四届董 ...

证券代码：688576 证券简称：西山科技 公告编号：2025-041 重庆西山科技股份有限公司 第四届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 会议经过审核、表决，通过以下决议： （一）审议通过《关于公司 2025 年第三季度财务报告的议案》 经审议，监事会认为公司 2025 年第三季度报告客观真实地反映了报告期内 公司的财务状况和经营成果，不存在任何虚假记载、误导性陈述或者重大遗漏。 因此，监事会一致同意本议案。 表决情况：同意 3 票，反对 0 票，弃权 0 票，回避 0 票。 具体内容详见公司同日披露于上海证券交易所网站（www.sse.com.cn）的《重 庆西山科技股份有限公司 2025 年第三季度报告》。 （二）审议通过《关于取消监事会及修订<公司章程>的议案》 经审议，监事会认为本次取消监事会系根据《公司法》《上市公司章程指引》 《上海证券交易所科创板股票上市规则》等法律、法规及规范性文件的规定，结 合公司实际情况而实施。公司取消监事会并修订《公司章程》等事宜，有利于贯 彻落 ...

Core Insights - Xishan Technology reported its third-quarter results, showing a revenue increase of 11.32% year-on-year, amounting to 230,800,606.31 yuan [1] - The net profit attributable to shareholders decreased by 34.14% year-on-year, totaling 43,395,010.59 yuan [1] Shareholder Changes - Among the top ten circulating shareholders, new entrants include Bank of China Co., Ltd. - Dacheng Jingheng Mixed Securities Investment Fund, Chongqing Zhongcheng No. 4 Enterprise Management Center (Limited Partnership), and Chongqing Zhongcheng No. 2 Enterprise Management Center (Limited Partnership) [1]

重庆西山科技股份有限公司 章 程 2025 年 10 月 1 | | | | | | 第一章 总 则 第一条 为维护重庆西山科技股份有限公司（以下简称"公司"）、股东和债 权人的合法权益，规范公司的组织和行为，根据《中华人民共和国公司法》（以 下简称"《公司法》"）、《中华人民共和国证券法》（以下简称"《证券法》"） 和其他有关规定，制订本章程。 第二条 公司系依照《公司法》和其他有关规定，由重庆西山科技有限公司 整体变更设立的股份有限公司。 第四条 公司注册名称 公司在重庆两江新区市场监督管理局注册登记，取得企业法人营业执照。统 一社会信用代码为 91500000203291805D。 中文名称：重庆西山科技股份有限公司 英文名称：Chongqing Xishan Science & Technology Co., Ltd 第五条 公司住所：重庆市两江新区康美街道康竹路 2 号 第三条 公司根据中国证监会于 2023 年 4 月 17 日出具的《关于同意重庆西 山科技股份有限公司首次公开发行股票注册的批复》（证监许可〔2023〕804 号）， 首次向社会公众发行人民币普通股 1,325.0367 万股，于 ...